Edgewise Therapeutics (EWTX) shares went up 29% in Thursday's premarket activity after announcing that EDG-7500, an investigational treatment for cardiomyopathy, was found to be well-tolerated in two early trials.
Results showed that EDG-7500 was well-tolerated in both a phase 1 study on healthy subjects and a phase 2 study on patients with obstructive hypertrophic cardiomyopathy, with no significant side effects such as changes in the heart's pumping of blood, Edgewise said.
Edgewise said it began dosing patients for a 28-day part of the obstructive ECM trial and initial results are expected in Q1 next year.
Price: 24.60, Change: +5.53, Percent Change: +28.98
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。